WO2016133255A1 - 혈액순환장애 측정 장치 및 그 방법 - Google Patents
혈액순환장애 측정 장치 및 그 방법 Download PDFInfo
- Publication number
- WO2016133255A1 WO2016133255A1 PCT/KR2015/008859 KR2015008859W WO2016133255A1 WO 2016133255 A1 WO2016133255 A1 WO 2016133255A1 KR 2015008859 W KR2015008859 W KR 2015008859W WO 2016133255 A1 WO2016133255 A1 WO 2016133255A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- pulse wave
- blood circulation
- value point
- electrocardiogram
- circulation disorder
- Prior art date
Links
- 230000017531 blood circulation Effects 0.000 title claims abstract description 62
- 238000000034 method Methods 0.000 title claims abstract description 38
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 105
- 208000026106 cerebrovascular disease Diseases 0.000 claims abstract description 45
- 208000019553 vascular disease Diseases 0.000 claims abstract description 21
- 238000004364 calculation method Methods 0.000 claims abstract description 11
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 49
- 201000010099 disease Diseases 0.000 claims description 43
- 210000001715 carotid artery Anatomy 0.000 claims description 14
- 230000005540 biological transmission Effects 0.000 claims description 11
- 210000000689 upper leg Anatomy 0.000 claims description 11
- 210000004556 brain Anatomy 0.000 claims description 2
- 238000012546 transfer Methods 0.000 claims description 2
- 238000005259 measurement Methods 0.000 abstract description 20
- 238000003745 diagnosis Methods 0.000 abstract description 9
- 238000001514 detection method Methods 0.000 abstract description 3
- 238000012216 screening Methods 0.000 abstract description 3
- 208000035475 disorder Diseases 0.000 description 36
- 238000004458 analytical method Methods 0.000 description 8
- 238000007477 logistic regression Methods 0.000 description 8
- 210000004204 blood vessel Anatomy 0.000 description 7
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 238000009795 derivation Methods 0.000 description 5
- 230000002526 effect on cardiovascular system Effects 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 201000001320 Atherosclerosis Diseases 0.000 description 3
- 210000001367 artery Anatomy 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 238000012935 Averaging Methods 0.000 description 2
- 238000009825 accumulation Methods 0.000 description 2
- 238000002591 computed tomography Methods 0.000 description 2
- 239000004065 semiconductor Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 230000002792 vascular Effects 0.000 description 2
- 230000036642 wellbeing Effects 0.000 description 2
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010020710 Hyperphagia Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033799 Paralysis Diseases 0.000 description 1
- 208000006011 Stroke Diseases 0.000 description 1
- 206010042434 Sudden death Diseases 0.000 description 1
- 208000007536 Thrombosis Diseases 0.000 description 1
- 238000002583 angiography Methods 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000000747 cardiac effect Effects 0.000 description 1
- 239000003518 caustics Substances 0.000 description 1
- 239000004020 conductor Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 235000006694 eating habits Nutrition 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 239000003344 environmental pollutant Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 210000003141 lower extremity Anatomy 0.000 description 1
- 238000002595 magnetic resonance imaging Methods 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 208000010125 myocardial infarction Diseases 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000020830 overeating Nutrition 0.000 description 1
- 210000000578 peripheral nerve Anatomy 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 230000010349 pulsation Effects 0.000 description 1
- 230000035485 pulse pressure Effects 0.000 description 1
- 230000000391 smoking effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000012285 ultrasound imaging Methods 0.000 description 1
- 230000006438 vascular health Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/026—Measuring blood flow
- A61B5/0285—Measuring or recording phase velocity of blood waves
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/021—Measuring pressure in heart or blood vessels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/021—Measuring pressure in heart or blood vessels
- A61B5/02108—Measuring pressure in heart or blood vessels from analysis of pulse wave characteristics
- A61B5/02125—Measuring pressure in heart or blood vessels from analysis of pulse wave characteristics of pulse wave propagation time
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/024—Detecting, measuring or recording pulse rate or heart rate
- A61B5/0245—Detecting, measuring or recording pulse rate or heart rate by using sensing means generating electric signals, i.e. ECG signals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/318—Heart-related electrical modalities, e.g. electrocardiography [ECG]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7235—Details of waveform analysis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/72—Signal processing specially adapted for physiological signals or for diagnostic purposes
- A61B5/7271—Specific aspects of physiological measurement analysis
- A61B5/7275—Determining trends in physiological measurement data; Predicting development of a medical condition based on physiological measurements, e.g. determining a risk factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/02007—Evaluating blood vessel condition, e.g. elasticity, compliance
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/02—Detecting, measuring or recording pulse, heart rate, blood pressure or blood flow; Combined pulse/heart-rate/blood pressure determination; Evaluating a cardiovascular condition not otherwise provided for, e.g. using combinations of techniques provided for in this group with electrocardiography or electroauscultation; Heart catheters for measuring blood pressure
- A61B5/024—Detecting, measuring or recording pulse rate or heart rate
- A61B5/02416—Detecting, measuring or recording pulse rate or heart rate using photoplethysmograph signals, e.g. generated by infrared radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/24—Detecting, measuring or recording bioelectric or biomagnetic signals of the body or parts thereof
- A61B5/316—Modalities, i.e. specific diagnostic methods
- A61B5/318—Heart-related electrical modalities, e.g. electrocardiography [ECG]
- A61B5/346—Analysis of electrocardiograms
- A61B5/349—Detecting specific parameters of the electrocardiograph cycle
- A61B5/352—Detecting R peaks, e.g. for synchronising diagnostic apparatus; Estimating R-R interval
Definitions
- the present invention relates to an apparatus for measuring blood circulation disorder using pulse wave propagation time, and more particularly, to a blood circulation disorder using pulse wave propagation time between pulse waves measured at different points or transfer time between pulse wave and electrocardiogram.
- the present invention relates to a blood circulation disorder measuring apparatus and a method thereof.
- Blood vessels are the lifeline that nourishes 60 trillion cells of our body.
- the blood discharged by the heartbeat must flow along the arteries throughout the body without clogging and return blood back to the heart through veins. In this way, oxygen and nutrients can be supplied to each tissue of the body, and waste products consumed through metabolism can be removed.
- vascular health is a direct part of our health, and poor vascular management can lead to serious diseases.
- Fats, blood clots and plaques build up on the inner walls of blood vessels, causing inflammation, and the accumulation of inflammatory substances accumulates and the walls of blood vessels become hard. Accumulation accumulates in the walls of blood vessels, narrowing blood vessels, causing blood and oxygen supply disorders, and various vascular diseases.
- Representative vascular diseases include, for example, angina pectoris, myocardial infarction, stroke, and lower extremity artery occlusion.
- the lack of sufficient blood and oxygen to the heart and brain, the key organs for life support can cause paralysis or sudden death.
- Cardiovascular and cerebrovascular diseases are the leading causes of death in the world as well as in Korea. These vascular diseases proceed silently and do not have any special symptoms until they are no longer blocked, resulting in irreversible conditions if neglected. Therefore, it is important to diagnose and prevent cardiovascular disease, cerebrovascular disease, and caustic arteriosclerosis risk factors early even in the absence of subjective symptoms.
- Invasive methods include angiography, in which a contrast medium is injected into a blood vessel, a method using a catheter, and microscopic ultrasonography in an artery.
- non-invasive methods include magnetic resonance imaging (MRI), computer tomography (CT), ultrasound imaging, ultrasound wave pulse rate (PWV) measurement, reflected waves
- MRI magnetic resonance imaging
- CT computer tomography
- PWV ultrasound wave pulse rate
- reflected waves There is an AI (Augmentation Index) measuring method that indicates the change in pulse pressure by the.
- AI Application Index
- Pulse waves are graphs of the wavelengths at which blood propagates in the heart.
- the pulse wave propagation time means the time taken for the pulse wave to move between two arterial pulsations, and the pulse wave propagation speed can be obtained by dividing the vessel length between two points for detecting the pulse wave by the propagated time difference. Hardening of the arterial vessels increases the rate of pulse wave delivery and is therefore used as a quantitative indicator of atherosclerosis.
- the technical problem to be achieved by the present invention is to provide an apparatus and method for measuring blood circulation disorders that can measure blood circulation disorders using pulse wave delivery time.
- measuring unit for measuring the pulse wave and electrocardiogram of the subject, the peak value of the measured ECG
- a detector for detecting the time information of the peak and the peak value of the point and pulse wave point, the peak value and the minimum value of the ECG and pulse waves detected for a certain period of time by the above method Computing the average value of the pulse wave transmission time using the time information of the point, and using this calculation unit for calculating the blood circulation disorder discrimination indicator, and a diagnostic unit for diagnosing blood circulation disorder using the calculated blood circulation disorder discrimination indicator do.
- the measurement unit may measure the pulse wave of at least one portion of the carotid artery, the upper arm, the radius and the femur.
- the calculator may calculate a disease group / normal group discrimination index for determining whether a vascular disease is present using an average of pulse wave propagation times between a peak value point of an electrocardiogram and a foot value point of pulse waves.
- the calculation unit may include EFf divided by EBf (EFf / EBf), EFf divided by ERf (EFf / ERf), CFf divided by CBf (CFf / CBf), and CFf divided by CRf (CFf /
- the disease group / normal group discrimination index may be calculated using at least one of CRf), and the EFf is a parameter representing an average of pulse wave propagation time between the maximum value point of ECG and the minimum value point of pulse wave measured at the thigh.
- the EBf is a parameter representing an average of pulse wave propagation time between the maximum value point of the electrocardiogram and the minimum value point of the pulse wave measured at the upper arm
- the ERf is the pulse wave propagation time between the maximum value point of the electrocardiogram and the minimum value point of the pulse wave measured at the radius.
- CFf is a parameter representing the mean
- CFf is a parameter representing the average of the pulse propagation time between the minimum value point of the pulse wave measured in the carotid artery and the femur
- CBf is the minimum value of the pulse wave measured in the carotid artery and the upper arm
- a parameter representing an average of the pulse wave propagation time between the CRf is the average of the pulse wave passes between the minimum points of the pulse waves measured at the carotid and radial time.
- the operation unit may calculate a cardiovascular disease group / cerebrovascular disease determination index for determining the type of vascular disease by using the average of the pulse wave transmission time between the peak value of the electrocardiogram and pulse wave.
- the calculating unit may include the cardiovascular vessel using at least one of ECp divided by a parameter EFp (ECp / EFp), parameter ECp divided by a parameter EBp (ECp / EBp), and ECp divided by ERp (ECp / ERp).
- the EFp is a parameter representing the average of the pulse wave propagation time between the maximum value point of the ECG and the maximum value of the pulse wave measured in the femoral region
- the EBp is the maximum of the ECG
- ERp is a parameter representing the average pulse wave propagation time between the maximum value point of the electrocardiogram and the pulse wave measured at the radius.
- the ECp represents the average of pulse wave propagation time between the maximum value point of the electrocardiogram and the maximum value point of the pulse wave measured in the carotid artery.
- the method for measuring blood circulation disorder using the pulse wave propagation time measuring the pulse wave and the electrocardiogram of the subject, the peak point of the measured electrocardiogram and the measured Detecting time information of a peak value point and a foot value point of a pulse wave, and calculating a pulse wave propagation time using time information of the detected peak value point and a foot value point And calculating a blood circulation disorder determination index using the pulse wave transmission time, and diagnosing a blood circulation disorder using the calculated blood circulation disorder determination index.
- the present invention in the future simple pulse transit time (Pulse transit time) measurement can be utilized for the primary screening of the normal group and the cardiovascular disease group.
- the present invention can be utilized in various parts, such as medical examination of the hospital, well-being platform (wellness platform) of the current national concern, and other personal health care programs.
- FIG. 1 is a block diagram showing a blood circulation disorder measuring apparatus according to an embodiment of the present invention.
- Figure 2a is a graph showing the analysis results of disease group / normal group discrimination index according to an embodiment of the present invention.
- Figure 2b is a graph showing the logistic regression results of the discrimination index of the disease group / normal group according to an embodiment of the present invention.
- Figure 3a is a graph showing the analysis results of cardiovascular disease group / cerebrovascular disease group discrimination indicator according to an embodiment of the present invention.
- Figure 3b is a graph showing the logistic regression results of the cardiovascular disease group / cerebrovascular disease discrimination index according to an embodiment of the present invention.
- Figure 4 is a flow chart showing a blood circulation disorder measuring method according to an embodiment of the present invention.
- FIG. 1 is a view showing the configuration of a blood circulation disorder measuring apparatus.
- the apparatus for measuring blood circulation disorder includes a measuring unit 110, a detecting unit 120, a calculating unit 130, and a diagnosing unit 140.
- the measuring unit 110 measures the electrocardiogram (EKG) and pulse wave of the human body to be measured.
- pulse wave refers to a pulse formed by the pulse transmitted to the peripheral nerve. If there is atherosclerosis, the shape of the wave changes and the speed of propagation increases.
- the measuring unit 110 may measure pulse waves at each part of the human body, and each part of the human body may include a carotid, a brachial, a radial, and a femoral.
- the measuring unit 110 may include an IR or semiconductor pulse wave signal acquisition sensor for measuring pulse waves.
- Electrocardiogram refers to the recording of electrical changes occurring locally by cardiac activity. Electric changes can be recorded on the body surface because they are transmitted to the body that makes up the volumetric conductors and reach the body surface. Humans usually record electrodes by attaching electrodes to specific parts of the body's surface.
- the measuring unit 110 measures the electrocardiogram of the human body, wherein the measuring method of the electrocardiogram includes the derivation method derived from both hands, the derivation method derived from the right hand-left foot, the derivation method derived from the left hand-left foot, and the derivation method by unipolar induction.
- the above derivation method is a well-known technique that can be easily implemented by those skilled in the art, and thus a detailed description thereof will be omitted.
- the measurement unit 110 transmits the data of the electrocardiogram and pulse wave measured from the measurement target to the detection unit 120.
- the detector 120 detects time information of peak and foot values through the pulse wave and electrocardiogram data received from the measurement unit 110.
- the detector 120 detects the time information of the maximum value point and the minimum value point from the pulse wave measurement data transmitted from the measurement unit 110 and the time information of the maximum value point from the ECG measurement data.
- the maximum value point of the ECG means the R point in the QRS group of the ECG.
- the detector 120 detects the time information of the maximum and minimum value points of the pulse wave and the time information of the maximum value point of the electrocardiogram from the data received from the measurement unit 110 and transmits the time information to the operation unit 130.
- the calculating unit 130 calculates an average of the pulse wave propagation time using time information on the maximum value point and the minimum value point of the pulse wave and the maximum value point of the electrocardiogram received from the detector 120.
- Table 1 is a table for explaining the parameter of the average value of the pulse wave propagation time using the minimum (foot) point of the pulse wave in accordance with an embodiment of the present invention.
- the parameter representing the average value of the pulse wave propagation time using the minimum point of the pulse wave includes EFf, EBf, ERf, CFf, CBf, and CRf, and may further include other parameters.
- the average value of the pulse wave propagation time using the minimum point of the pulse wave means a value obtained by averaging the time between the foot values of each period detected in the pulse wave.
- EFf is a parameter representing the average pulse wave propagation time between the maximum value point of ECG and the minimum value point of the pulse wave measured at the thigh
- EBf is the maximum value point of the ECG and the minimum value point of the pulse wave measured at the upper arm. This parameter represents the average of pulse wave propagation time.
- ERf is a parameter representing the average of the pulse wave propagation time between the maximum value point of the electrocardiogram and the minimum value of the pulse wave measured in the radial
- CFf is a parameter representing the average of the pulse wave transmission time between the minimum value point of the pulse wave measured in the carotid artery and thigh to be.
- CBf is a parameter representing the average pulse wave propagation time between the minimum value point of the pulse wave measured in the carotid artery and the upper arm
- CRf is a parameter representing the average pulse wave propagation time between the minimum value point of the pulse wave measured in the carotid artery and the radial arm.
- Table 2 is a table for explaining a parameter of the average value of the pulse wave propagation time using the peak value of the pulse wave in accordance with an embodiment of the present invention.
- the parameter representing the average value of the pulse wave propagation time using the peak value of the pulse wave includes EFp, EBp, ERp, and ECp, and may further include other parameters.
- the average value of the pulse wave propagation time using the peak point of the pulse wave means a value obtained by averaging time between peak values of each period detected in the pulse wave.
- EFp is a parameter representing the average of pulse wave propagation time between the maximum value point of ECG and the maximum value of pulse wave measured at the thigh
- EBp is the pulse wave transmission between the maximum value point of ECG and the maximum value of pulse wave measured at the upper arm. This parameter represents the average of time.
- ERp is a parameter representing the average of the pulse wave propagation time between the maximum value point of the electrocardiogram and the pulse wave maximum point measured in the radial
- ECp is the pulse wave transmission between the maximum value point of the electrocardiogram and the pulse point measured in the carotid artery This parameter represents the average of time.
- the calculating unit 130 may calculate the blood circulation disorder determination index by using a parameter representing the average of the pulse wave transmission time.
- Blood circulation disorder discrimination indicators include disease / normal group discrimination index and cardiovascular disease / cerebrovascular disease discrimination index.
- the disease group / normal group discrimination index calculated by the operation unit 130 using a parameter representing an average of pulse wave propagation time using the minimum point of the pulse wave will be described.
- Distinguishing indicators of the disease group and the normal group includes A1 to A11, and may further include other disease group / normal group discrimination indicators.
- Disease group / normal group discrimination indexes A1 to A4 are calculated using a parameter representing an average of pulse wave propagation times using the minimum point value of the pulse wave.
- Disease group / normal group discrimination index A1 represents parameter EFf divided by parameter EBf (EFf / EBf), and disease group / normal group discrimination index A2 represents parameter EFf divided by parameter ERf (EFf / ERf).
- Disease group / normal group discrimination index A3 represents the parameter CFf divided by parameter CBf (CFf / CBf), and disease group / normal group discrimination index A4 represents the parameter CFf divided by parameter CRf (CFf / CRf).
- the disease group / normal group discrimination indexes A5 to A10 are calculated using the disease group / normal group discrimination indexes A1 to A4.
- Disease group / normal group discrimination index A5 is a discrimination index indicating the sum of two items among disease group / normal group discrimination indexes A1 to A4.A1 + A2, A1 + A3, A1 + A4, A2 + A3, A2 + It may have any one of A4 and A3 + A4.
- A6 is a discrimination index indicating the sum of three items among A1 to A4.A1 + A2 + A3, A1 + A2 + A4, A1 + A3 + A4, A2 + A3 + A4 It can have one value.
- the disease group / normal group discrimination index A7 is a discrimination index obtained by adding A1 to A4 and may have a value of A1 + A2 + A3 + A4.
- Disease group / normal group discrimination index A8 is a discrimination index indicating a multiplication value of two items among A1 to A4, and among A1 * A2, A1 * A3, A1 * A4, A2 * A3, A2 * A4, and A3 * A4 It can have either value.
- Disease group / normal group discrimination index A9 is a discrimination index indicating a multiplication value for three items among A1 to A4, among A1 * A2 * A3, A1 * A2 * A4, A1 * A3 * A4, and A2 * A3 * A4. It can have either value.
- the disease / normal group discrimination index A10 is a discrimination index obtained by adding A1 to A4 and may have a value of A1 * A2 * A3 * A4.
- disease / normal group discrimination index A11 represents the sum of two values among the values of the disease group / normal group discrimination index A8. Therefore, disease / normal group discrimination index A11 is (A1 * A2) + (A1 * A3), (A1 * A2) + (A1 * A4), (A1 * A2) + (A2 * A3), (A1 * A2) + (A2 * A4), (A1 * A2) + (A3 * A4), (A1 * A3) + (A1 * A4), (A1 * A3) + (A2 * A3), (A1 * A3) + (A2 * A4), (A1 * A3) + (A3 * A4), (A1 * A4) + (A2 * A3), (A1 * A4) + (A2 * A4), (A1 * A4) + (A2 * A4), (A1 * A4) + (A3 * A4), (A2 * A3) + (A2 * A4), (A1 * A4) + (A2 * A
- Cardiovascular disease group / cerebrovascular disease discrimination indicators include B1 to B8 and may further include other cardiovascular disease / cerebrovascular disease discrimination indicators.
- the cardiovascular disease group / cerebrovascular disease determination index B1 to B3 is calculated using a parameter representing the average of the pulse wave delivery time using the peak value of the pulse wave (peak) point.
- Cardiovascular disease group / cerebrovascular disease discrimination indicator B1 represents the parameter ECp divided by the parameter EFp (ECp / EFp), and cardiovascular disease / cerebrovascular disease discrimination index B2 is the parameter ECp divided by the parameter EBp (ECp). / EBp).
- cardiovascular disease group / cerebrovascular disease group discrimination index B3 represents the value of the parameter ECp divided by the parameter ERp (ECp / ERp).
- the cardiovascular disease group / cerebrovascular disease group discrimination indexes B4 to B8 are calculated using the cardiovascular disease group / cerebrovascular disease group discrimination indexes B1 to B3.
- Cardiovascular disease group / cerebrovascular disease discrimination indicator B4 is the sum of the discrimination index of the cardiovascular disease group / cerebrovascular disease group discrimination indicators B1 to B3 for the two items, the value of B1 + B2, B1 + B3, B2 + B3 It may have any one of.
- Cardiovascular disease group / cerebrovascular disease discrimination index B5 is a total sum of the B1 to B3 discrimination index, it may have a value of B1 + B2 + B3.
- Cardiovascular disease group / cerebrovascular disease discrimination index B6 is a discrimination index showing the multiplication value of two items of cardiovascular disease / cerebrovascular disease group discrimination index B1 to B3, B1 * B2, B1 * B3, B2 * B3 It can have any one of the values of.
- the cardiovascular disease group / cerebrovascular disease discrimination index B7 is a discrimination index indicating a total multiplication value of B1 to B3 and may have a value of B1 * B2 * B3.
- the cardiovascular disease group / cerebrovascular disease discrimination index B8 is the sum of two values of the cardiovascular disease / cerebrovascular disease discrimination index B6, and it is (B1 * B2) + (B1 * B3) and (B1). It may have any one of * B2) + (B2 * B3) and (B1 * B3) + (B2 * B3).
- the calculating unit 130 determines the calculated blood circulation disorder.
- the indicator is transmitted to the diagnosis unit 140.
- the blood circulation disorder discrimination index includes disease / normal group discrimination index (A1 to A11) and cardiovascular disease group / cerebrovascular disease discrimination index (B1 to B8).
- the diagnosis unit 140 diagnoses the blood circulation disorder by using the blood circulation disorder discrimination indicator received from the operation unit 130.
- the diagnosis unit 140 may determine whether the disease is a vascular disease through the disease group / normal group discrimination indicators A1 to A11 received from the calculator 130.
- the diagnosis unit 140 may determine whether the type of vascular disease is a cardiovascular disease or a cerebrovascular disease through the cardiovascular disease group / cerebrovascular disease group determination indicators B1 to B8 received from the operation unit 130.
- FIGS. 2A and 2B exemplarily show an analysis result for disease group / normal group discrimination index A7.
- Table 3 shows the diagnostic criteria for determining the disease group and the normal group according to an embodiment of the present invention.
- the range of A7 indicator values corresponding to the boundary area ranges from 4.12 to 4.36, and if it exceeds 4.36, it corresponds to the normal group. If it is less than 4.12, it corresponds to the disease group.
- the threshold for discriminating between the disease group and the normal group is an experimentally obtained value, which can be changed according to the results of the clinical trial.
- Figure 2a is a graph showing the results of the analysis of the discrimination indicator of the disease group / normal group according to an embodiment of the present invention.
- Figure 2b is a graph showing the logistic regression results of the disease group / normal group discrimination index according to an embodiment of the present invention.
- the estimated probability is set to 50% and the boundary area is set at a ratio from side to side to calculate sensitivity and specificity for the vascular disease group and the normal group. It was. A case where the estimated probability is 0 is a vascular disease group, and a case where 1 is a normal group.
- the estimated probability is based on 50%, and the sensitivity and specificity for the vascular disease group and the normal group when the left 10% area and the right 20% area are set as the boundary area.
- the specificities were 90% each.
- 3A and 3B will be described for the determination of cardiovascular disease.
- 3A and 3B exemplarily show an analysis result of the discrimination index for the B1 + B3 value, that is, the (ECp / EFp) + (ECp / ERp) value in the cardiovascular disease group / cerebrovascular disease discrimination index B4.
- Table 4 shows the diagnostic criteria for determining the cardiovascular disease group and cerebrovascular disease group according to an embodiment of the present invention.
- the range of B4-2 indicator values (B1 + B3, ie, (ECp / EFp) + (ECp / ERp)) corresponding to the boundary area ranges from 1.89 to 2.17, which exceeds 2.17.
- the threshold for discriminating the cardiovascular disease group and the cerebrovascular disease group is an experimentally obtained value and may be changed according to the results of the clinical experiment.
- Figure 3a is a graph showing the analysis results of cardiovascular disease group / cerebrovascular disease group discrimination indicator according to an embodiment of the present invention.
- Cardiovascular disease group / cerebrovascular disease discrimination indicators analysis results cardiovascular disease group (1) in the cardiovascular disease / cerebrovascular disease group discrimination indicators B4-2 value was found to be concentrated around 1.75 lower than 1.89 Can be. On the other hand, in the cerebrovascular disease group (2), the value of the cardiovascular disease group / cerebrovascular disease discrimination index B4-2 can be seen to be distributed around 2.25 higher than 2.17.
- Figure 3b is a graph showing the logistic regression results of the cardiovascular disease group / cerebrovascular disease discrimination index according to an embodiment of the present invention.
- the estimated probability was set to 50% and the boundary area was set at a ratio from side to side to calculate sensitivity and specificity for the cardiovascular disease group.
- the cardiovascular disease group is 1, and the case where 1 is the cerebrovascular disease group.
- the estimated probability is based on 50%, and the sensitivity and specificity for cardiovascular disease group is set when the 30% left and 15% right areas are used as boundary areas. specificity) was 90%.
- Figure 4 is a flow chart showing a blood circulation disorder measuring method according to an embodiment of the present invention.
- the measurement unit 110 measures the electrocardiogram and pulse wave of the measurement target (S410).
- the measuring unit 110 may measure pulse waves at each part of the human body, and each part of the human body may include a carotid, a brachial, a radial, and a femoral.
- the measuring unit 110 may include an IR or semiconductor pulse wave signal acquisition sensor for measuring pulse waves.
- the measurement unit 110 transmits the measured electrocardiogram data and pulse wave data to the detection unit 120.
- the detector 120 detects time information on peak values of the electrocardiogram, peak values of the electrocardiogram, and peak and minimum values of the pulse waves using the electrocardiogram data and the pulse wave data transmitted from the measuring unit 110. (S420).
- the detector 120 transmits the time information of the maximum value and the minimum value point of the pulse wave and the maximum value point of the ECG, that is, the time information of the R point of the QRS group, to the calculation unit 130.
- the calculating unit 130 calculates a pulse transit time using time information of the maximum value point of the ECG received from the detector 120 and time information of the maximum value and the minimum value point of the pulse wave (S430).
- the calculator 130 may calculate the parameters EFf, EBf, ERf, CFf, CBf, and CRf representing the average value of the pulse wave propagation time using the time information of the minimum value point of the pulse wave.
- the calculation unit 130 may calculate parameters EFp, EBp, ERp, and ECp representing the average of the pulse wave propagation time using time information of the peak value of the pulse wave.
- the calculation unit 130 may calculate the blood circulation disorder determination index by using the parameter of calculating the average value of the pulse wave propagation time using the time information of the maximum and minimum value points of the pulse wave and the time information of the maximum value point of the electrocardiogram. It may be (S440).
- the blood circulation disorder discrimination index may include discrimination indexes (A1 to A11) for discriminating a disease group and a normal group, and discrimination indexes (B1 to B8) for discriminating cardiovascular and cerebrovascular diseases.
- the operation unit 130 calculates a blood circulation disorder determination index and transmits it to the diagnosis unit 140.
- the diagnosis unit 140 determines the blood circulation disorder by using the blood circulation disorder determination indicator received from the calculator 130 (S450).
- the diagnosis unit 140 compares the calculated blood circulation disorder determination index with a threshold, and determines whether the measurement target is included in the vascular disease group and the normal group, and whether the cardiovascular disease and the cerebrovascular disease.
- the present invention in the future simple pulse transit time (Pulse transit time) measurement can be utilized for the primary screening of the normal group and the cardiovascular disease group.
- the present invention can be utilized in various parts, such as medical examination of the hospital, well-being platform (wellness platform) of the current national concern, and other personal health care programs.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Cardiology (AREA)
- Public Health (AREA)
- Surgery (AREA)
- Veterinary Medicine (AREA)
- Physics & Mathematics (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Animal Behavior & Ethology (AREA)
- Physiology (AREA)
- Hematology (AREA)
- Signal Processing (AREA)
- Vascular Medicine (AREA)
- Psychiatry (AREA)
- Computer Vision & Pattern Recognition (AREA)
- Artificial Intelligence (AREA)
- Measuring Pulse, Heart Rate, Blood Pressure Or Blood Flow (AREA)
- Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
Abstract
Description
파라미터 | 의미 |
EFf | EKG R peak - femoral pulse wave foot 간의 Pulse transit time 평균 |
EBf | EKG R peak - brachial pulse wave foot 간의 Pulse transit time 평균 |
ERf | EKG R peak - radial pulse wave foot 간의 Pulse transit time 평균 |
CFf | carotid - femoral pulse wave foot 간의 Pulse transit time 평균 |
CBf | carotid - brachial pulse wave foot 간의 Pulse transit time 평균 |
CRf | carotid - radial pulse wave foot 간의 Pulse transit time 평균 |
파라미터 | 의미 |
EFp | EKG R peak - femoral pulse wave peak 간의 Pulse transit time 평균 |
EBp | EKG R peak - brachial pulse wave peak 간의 Pulse transit time 평균 |
ERp | EKG R peak - radial pulse wave peak 간의 Pulse transit time 평균 |
ECp | EKG R peak - carotid pulse wave peak 간의 Pulse transit time 평균 |
A7 지표 | 진단기준 |
정상군 | 4.36 초과 |
경계영역 | 4.12 ~ 4.36 |
질환군 | 4.12 미만 |
B4-2 지표 | 진단기준 |
뇌혈관 질환 | 2.17 초과 |
경계영역 | 1.89 ~ 2.17 |
심혈관 질환 | 1.89 미만 |
Claims (10)
- 맥파전달시간을 이용한 혈액순환장애 측정 장치에 있어서,측정 대상자의 맥파 및 심전도를 측정하는 측정부,상기 측정된 심전도의 최대(peak)값 지점 및 맥파의 최대(peak)값 지점과 최소(foot)값 지점의 시간정보를 검출하는 검출부,상기 검출된 심전도의 최대(peak)값 지점 및 맥파의 최대(peak)값 지점과 최소(foot)값 지점의 시간정보를 이용하여 맥파전달시간의 평균값을 계산하고, 이를 이용하여 혈액순환장애 판별 지표를 연산하는 연산부, 그리고상기 연산된 혈액순환장애 판별지표를 이용하여 혈액순환장애를 진단하는 진단부를 포함하는 혈액순환장애 측정 장치.
- 제1항에 있어서,상기 측정부는,경동맥, 상완, 요골 및 대퇴부 중 적어도 어느 한 부위의 맥파를 측정하는 혈액순환장애 측정 장치.
- 제2항에 있어서,상기 연산부는,심전도의 최고(peak)값 지점과 맥파의 최소(foot)값 지점 사이의 맥파전달시간의 평균을 이용하여 혈관 질환 여부를 판별하는 질환군/정상군 판별지표를 연산하는 혈액순환장애 측정 장치.
- 제3항에 있어서,상기 연산부는,EFf를 EBf로 나눈 값(EFf/EBf), EFf를 ERf로 나눈 값(EFf/ERf), CFf를 CBf로 나눈 값(CFf/CBf), 및 CFf를 CRf로 나눈 값(CFf/CRf) 중에서 적어도 하나를 이용하여 상기 질환군/정상군 판별지표를 연산하며,상기 EFf는 심전도의 최대값 지점과 대퇴부에서 측정된 맥파의 최소값 지점간의 맥파전달시간의 평균을 나타내는 파라미터이고, 상기 EBf는 심전도의 최대값 지점과 상완에서 측정된 맥파의 최소값 지점간의 맥파전달시간의 평균을 나타내는 파라미터이며, 상기 ERf는 심전도의 최대값 지점과 요골에서 측정된 맥파의 최소값 지점간의 맥파전달시간의 평균을 나타내는 파라미터이고, CFf는 경동맥과 대퇴부에서 측정된 맥파의 최소값 지점간의 맥파전달시간의 평균을 나타내는 파라미터이며, 상기 CBf는 경동맥과 상완에서 측정된 맥파의 최소값 지점간의 맥파전달시간의 평균을 나타내는 파라미터이고, 상기 CRf는 경동맥과 요골에서 측정된 맥파의 최소값 지점간의 맥파전달시간의 평균을 나타내는 파라미터인 혈액순환장애 측정 장치.
- 제2항에 있어서,상기 연산부는,심전도 및 맥파의 최고(peak)값 지점 사이의 맥파전달시간의 평균을 이용하여 혈관 질환의 종류를 판별하는 심혈관질환군/뇌혈관질환군 판별지표를 연산하는 혈액순환장애 측정 장치.
- 제5항에 있어서,상기 연산부는,ECp를 파라미터 EFp로 나눈 값(ECp/EFp), 파라미터 ECp를 파라미터 EBp로 나눈 값(ECp/EBp) 및 ECp를 ERp로 나눈 값(ECp/ERp) 중에서 적어도 하나를 이용하여 상기 심혈관질환군/뇌혈관질환군 판별지표를 연산하며,상기 EFp는 심전도의 최대값 지점과 대퇴부에서 측정된 맥파의 최대값 지점간의 맥파전달시간의 평균을 나타내는 파라미터이고, 상기 EBp 는 심전도의 최대값 지점과 상완에서 측정된 맥파의 최대값 지점간의 맥파전달시간의 평균을 나타내는 파라미터이며, 상기 ERp 는 심전도의 최대값 지점과 요골에서 측정된 맥파의 최대값 지점간의 맥파전달시간의 평균을 나타내는 파라미터이고, 상기 ECp 는 심전도의 최대값 지점과 경동맥에서 측정된 맥파의 최대값 지점간의 맥파전달시간의 평균을 나타내는 파라미터인 혈액순환장애 측정 장치.
- 맥파전달시간을 이용하여 혈액순환장애를 측정하는 방법에 있어서,측정 대상자의 맥파 및 심전도를 측정하는 단계,상기 측정된 심전도의 최대(peak)값 지점 및 측정된 맥파의 최대(peak)값 지점과 최소(foot)값 지점의 시간정보를 검출하는 단계,상기 검출된 최대(peak)값 지점과 최소(foot)값 지점의 시간정보를 이용하여 맥파전달시간을 계산하는 단계,상기 맥파전달시간을 이용하여 혈액순환장애 판별지표를 연산하는 단계, 그리고상기 연산된 혈액순환장애 판별지표를 이용하여 혈액순환장애를 진단하는 단계를 포함하는 혈액순환장애 측정 방법.
- 제7항에 있어서,상기 맥파 및 심전도를 측정하는 단계는,경동맥, 상완, 요골 및 대퇴부 중 적어도 어느 한 부위의 맥파를 측정하는 혈액순환장애 측정 방법.
- 제7항에 있어서,상기 검출된 최대(peak)값 지점과 최소(foot)값 지점의 시간정보를 이용하여 맥파전달시간을 계산하고 혈액순환장애 판별지표를 연산하는 단계는,심전도의 최고(peak)값 지점과 맥파의 최소(foot)값 지점 사이의 맥파전달시간의 평균을 이용하여 혈관 질환 여부를 판별하는 질환군/정상군 지표를 연산하는 혈액순환장애 측정 방법.
- 제7항에 있어서,상기 검출된 최대(peak)값 지점과 최소(foot)값 지점의 시간정보를 이용하여 맥파전달시간을 계산하고 혈액순환장애 판별지표를 연산하는 단계는,심전도 및 맥파의 최고(peak)값 지점 사이의 맥파전달시간의 평균을 이용하여 혈관 질환 종류를 판별하는 심혈관질환군/뇌혈관질환군 지표를 연산하는 혈액순환장애 측정 방법.
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017558343A JP6725533B2 (ja) | 2015-01-26 | 2015-08-25 | 血行障害測定装置 |
US15/546,245 US11083385B2 (en) | 2015-01-26 | 2015-08-25 | Apparatus for measuring blood circulation disorders, and method therefor |
CN201580076894.5A CN107427245A (zh) | 2015-01-26 | 2015-08-25 | 血液循环障碍测量装置及其方法 |
EP15882788.1A EP3251593B1 (en) | 2015-01-26 | 2015-08-25 | Apparatus for measuring blood circulation disorders |
AU2015383230A AU2015383230A1 (en) | 2015-01-26 | 2015-08-25 | Apparatus for measuring blood circulation disorders, and method therefor |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR10-2015-0012097 | 2015-01-26 | ||
KR1020150012097A KR101646439B1 (ko) | 2015-01-26 | 2015-01-26 | 혈액순환장애 측정 장치 및 그 방법 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2016133255A1 true WO2016133255A1 (ko) | 2016-08-25 |
Family
ID=56692619
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2015/008859 WO2016133255A1 (ko) | 2015-01-26 | 2015-08-25 | 혈액순환장애 측정 장치 및 그 방법 |
Country Status (7)
Country | Link |
---|---|
US (1) | US11083385B2 (ko) |
EP (1) | EP3251593B1 (ko) |
JP (1) | JP6725533B2 (ko) |
KR (1) | KR101646439B1 (ko) |
CN (1) | CN107427245A (ko) |
AU (1) | AU2015383230A1 (ko) |
WO (1) | WO2016133255A1 (ko) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10842464B2 (en) * | 2015-05-28 | 2020-11-24 | Koninklijke Philips N.V. | Apparatus and method for determining blood flow velocity |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007111244A (ja) * | 2005-10-20 | 2007-05-10 | Seiko Instruments Inc | 血液循環状態測定装置 |
KR20080017525A (ko) * | 2006-08-21 | 2008-02-27 | 한양대학교 산학협력단 | 혈압 조절기능 측정 장치 및 프로그램이 기록된 기록매체. |
JP2010148690A (ja) * | 2008-12-25 | 2010-07-08 | Idm:Kk | 血液情報抽出装置 |
KR20130095664A (ko) * | 2012-02-20 | 2013-08-28 | 연세대학교 원주산학협력단 | 맥압과 맥파를 이용한 혈액순환장애 측정 시스템 |
KR20140148074A (ko) * | 2013-06-21 | 2014-12-31 | 가톨릭관동대학교산학협력단 | 맥파와 심전도를 이용한 혈류속도 측정장치 |
Family Cites Families (21)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5099853A (en) * | 1986-12-25 | 1992-03-31 | Colin Electronics Co., Ltd. | Blood pressure monitoring system |
JPH082350B2 (ja) * | 1987-05-02 | 1996-01-17 | コ−リン電子株式会社 | 脈波検出装置 |
JPH053858A (ja) * | 1991-06-28 | 1993-01-14 | Colleen Denshi Kk | 血圧モニタ装置 |
US6331162B1 (en) * | 1999-02-01 | 2001-12-18 | Gary F. Mitchell | Pulse wave velocity measuring device |
FR2794961B1 (fr) * | 1999-06-16 | 2001-09-21 | Global Link Finance | Procede de determination du decalage temporel entre les instants de passage d'une meme onde de pouls en deux points de mesure distincts d'un reseau arteriel d'un etre vivant et d'estimation de sa pression aortique |
JP2004313468A (ja) * | 2003-04-16 | 2004-11-11 | Omron Healthcare Co Ltd | 脈波測定装置および生体波解析プログラム |
CN1698536A (zh) * | 2004-05-20 | 2005-11-23 | 香港中文大学 | 采用自动补偿的无袖带式连续血压测量方法 |
US7621876B2 (en) * | 2005-03-17 | 2009-11-24 | Ge Medical Systems Information Technologies, Inc. | Continuous, non-invasive technique for determining blood pressure using a transmission line model and transcutaneous ultrasound measurements |
TWI258359B (en) * | 2005-05-20 | 2006-07-21 | Dailycare Biomedical Inc | Apparatus for evaluating cardiovascular functions |
CN101006915A (zh) * | 2006-01-26 | 2007-08-01 | 香港中文大学 | 非接触式关键生理参数测量方法 |
US20080027330A1 (en) * | 2006-05-15 | 2008-01-31 | Endothelix, Inc. | Risk assessment method for acute cardiovascular events |
US20080221461A1 (en) * | 2007-03-05 | 2008-09-11 | Triage Wireless, Inc. | Vital sign monitor for cufflessly measuring blood pressure without using an external calibration |
US8047998B2 (en) * | 2007-04-17 | 2011-11-01 | General Electric Company | Non-invasive blood pressure determination method |
US8419649B2 (en) * | 2007-06-12 | 2013-04-16 | Sotera Wireless, Inc. | Vital sign monitor for measuring blood pressure using optical, electrical and pressure waveforms |
CN201088579Y (zh) * | 2007-08-06 | 2008-07-23 | 北京麦邦光电仪器有限公司 | 一种动脉硬化检测和评估装置 |
KR101124641B1 (ko) * | 2008-10-02 | 2012-03-22 | 현석산 | 뇌혈관 분석 장치 |
JP5687994B2 (ja) * | 2010-11-09 | 2015-03-25 | 日本光電工業株式会社 | 生体信号測定装置および生体信号測定方法 |
ES2398439B1 (es) * | 2011-07-29 | 2014-03-05 | Universitat Politècnica De Catalunya | Método y aparato para obtener información cardiovascular midiendo entre dos extremidades |
WO2014022906A1 (en) | 2012-08-10 | 2014-02-13 | Cnv Systems Ltd. | Mobile device system for measurement of cardiovascular health |
US20140073969A1 (en) * | 2012-09-12 | 2014-03-13 | Neurosky, Inc. | Mobile cardiac health monitoring |
CN103598876B (zh) * | 2013-11-22 | 2016-08-17 | 哈尔滨工业大学深圳研究生院 | 数据处理方法及系统 |
-
2015
- 2015-01-26 KR KR1020150012097A patent/KR101646439B1/ko active IP Right Grant
- 2015-08-25 AU AU2015383230A patent/AU2015383230A1/en not_active Abandoned
- 2015-08-25 CN CN201580076894.5A patent/CN107427245A/zh active Pending
- 2015-08-25 WO PCT/KR2015/008859 patent/WO2016133255A1/ko active Application Filing
- 2015-08-25 JP JP2017558343A patent/JP6725533B2/ja active Active
- 2015-08-25 EP EP15882788.1A patent/EP3251593B1/en active Active
- 2015-08-25 US US15/546,245 patent/US11083385B2/en active Active
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007111244A (ja) * | 2005-10-20 | 2007-05-10 | Seiko Instruments Inc | 血液循環状態測定装置 |
KR20080017525A (ko) * | 2006-08-21 | 2008-02-27 | 한양대학교 산학협력단 | 혈압 조절기능 측정 장치 및 프로그램이 기록된 기록매체. |
JP2010148690A (ja) * | 2008-12-25 | 2010-07-08 | Idm:Kk | 血液情報抽出装置 |
KR20130095664A (ko) * | 2012-02-20 | 2013-08-28 | 연세대학교 원주산학협력단 | 맥압과 맥파를 이용한 혈액순환장애 측정 시스템 |
KR20140148074A (ko) * | 2013-06-21 | 2014-12-31 | 가톨릭관동대학교산학협력단 | 맥파와 심전도를 이용한 혈류속도 측정장치 |
Non-Patent Citations (1)
Title |
---|
See also references of EP3251593A4 * |
Also Published As
Publication number | Publication date |
---|---|
KR101646439B1 (ko) | 2016-08-08 |
US11083385B2 (en) | 2021-08-10 |
CN107427245A (zh) | 2017-12-01 |
EP3251593B1 (en) | 2022-06-29 |
JP6725533B2 (ja) | 2020-07-22 |
EP3251593A1 (en) | 2017-12-06 |
JP2018508323A (ja) | 2018-03-29 |
EP3251593A4 (en) | 2018-08-22 |
US20170367595A1 (en) | 2017-12-28 |
KR20160092101A (ko) | 2016-08-04 |
AU2015383230A1 (en) | 2017-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Aboukhalil et al. | Reducing false alarm rates for critical arrhythmias using the arterial blood pressure waveform | |
Choi et al. | Slow-wave sleep estimation on a load-cell-installed bed: a non-constrained method | |
US20140031709A1 (en) | Apparatus and method for identifying myocardial ischemia using analysis of high frequency qrs potentials | |
Nepi et al. | Validation of the heart-rate signal provided by the Zephyr bioharness 3.0 | |
Graham et al. | Associations between heart rate variability measured with a wrist-worn sensor and older adults’ physical function: observational study | |
Saghir et al. | A comparison of manual electrocardiographic interval and waveform analysis in lead 1 of 12-lead ECG and Apple Watch ECG: a validation study | |
US20180125384A1 (en) | Data processing apparatus for assessing a condition of a myocardium | |
Roy et al. | Comparison of electrocardiogram quality and clinical interpretations using prepositioned ECG electrodes and conventional individual electrodes | |
WO2016133255A1 (ko) | 혈액순환장애 측정 장치 및 그 방법 | |
Striepe et al. | Use of the Apple Watch iECG in adult congenital heart disease patients | |
Morag et al. | Do patients with a negative Emergency Department evaluation for syncope require hospital admission? | |
WO2017146303A1 (ko) | 맥파전달시간을 이용한 혈액순환장애 진단 장치 및 이를 이용한 혈액순환장애 진단 방법 | |
Thomaseth et al. | Heart rate spectral analysis for assessing autonomic regulation in diabetic patients | |
KR101231421B1 (ko) | 비 침습에 의한 심혈관질환에 대한 건강검진 시스템 | |
Lee et al. | Prediabetes and blood pressure effects on heart rate variability, QT-interval duration, and left ventricular hypertrophy in overweight-obese adolescents | |
Cheshmedzhiev et al. | Electronic sensor system for registering ECG and PPG signals | |
Wahyu Kusuma et al. | Design of arrhythmia detection device based on fingertip pulse sensor | |
KR101839758B1 (ko) | 혈액순환장애 측정 장치 및 그 방법 | |
KR101692742B1 (ko) | 혈액순환장애 측정 장치 및 그 방법 | |
KR101692743B1 (ko) | 혈액순환장애 측정 장치 및 그 방법 | |
Shellhaas et al. | American Clinical Neurophysiology Society's guideline on continuous EEG monitoring in neonates | |
Ostrowska et al. | Prevalence of electrocardiographic left ventricular hypertrophy among patients with coronary artery disease and diabetes mellitus | |
Murray | Computerized QT and QTc Measurements from Bedside ICU Monitors are Similar to those Derived from a Standard 12-lead ECG | |
Klinge et al. | Towards automatic pathology classification for a 24/7 ECG-based telemonitoring service | |
Do et al. | Predicting severe angiographic coronary artery disease using computerization of clinical and exercise test data |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 15882788 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2017558343 Country of ref document: JP Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 15546245 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2015882788 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: 2015383230 Country of ref document: AU Date of ref document: 20150825 Kind code of ref document: A |